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ABSTRACT
G
enome-wide association scans (GWASs) using single
nucleotide polymorphisms (SNPs) have been
completed successfully for several common
disorders and have detected over 30 new associations.
Considering the large sample sizes and genome-wide SNP
coverage of the scans, one might have expected many of the
common variants underpinning the genetic component of
various disorders to have been identiﬁed by now. However,
these studies have not evaluated the contribution of other
forms of genetic variation, such as structural variation,
mainly in the form of copy number variants (CNVs). Known
CNVs account for over 15% of the assembled human genome
sequence. Since CNVs are not easily tagged by SNPs, might
have a wide range of copy number variability, and often fall in
genomic regions not well covered by whole-genome arrays or
not genotyped by the HapMap project, current GWASs have
largely missed the contribution of CNVs to complex
disorders. In fact, some CNVs have already been reported to
show association with several complex disorders using
candidate gene/region approaches, underpinning the
importance of regions not investigated in current GWASs.
This reveals the need for new generation arrays (some already
in the market) and the use of tailored approaches to explore
the full dimension of genome variability beyond the single
nucleotide scale.
Introduction
A large number of studies describing GWASs has been
published recently. Several old and new associations have
been detected by genotyping large collections of samples with
hundred thousands of markers. Proof of concept of GWASs
has been demonstrated and new biological pathways are now
on the priority list of several investigators trying to
understand asthma, Crohn disease, and diabetes, among
other disorders. However, for most diseases, the identiﬁed
genomic regions explain only a small fraction of the familial
aggregation. Although these studies have been focused on
SNPs as the common resource to explore genetic variability,
other types of markers exist, which likely exert important
phenotypic effects on gene expression and function. In this
review, we explore the contribution of CNVs to common
human disorders and evaluate the caveats of SNP-based
GWASs in covering regions of the genome that have a high
degree of plasticity and that could play an important role in
disease susceptibility.
What Have We Missed in Current Genome-Wide
Association Studies?
SNPs are the markers that have been selected to do the
trick of uncovering the genetic determinants of complex
traits and common disorders. This choice was mainly based
on their abundance (over 12 million SNPs), and their use was
boosted by the technological development of tools for high-
throughput analysis of these variants. The Human Genome
Project, followed by the HapMap Project [1] (http://www.
hapmap.org/), has provided the landmark for the
development of high-density SNP arrays to explore the
nucleotide variability of the human genome, using powerful
analytical methods based on statistical genetics, population
genetics, and epidemiology.
Current association studies for common disorders and
complex traits, aim to detect linkage disequilibrium (LD)
between SNPs that genetically mark a given region (tagSNPs)
andthe functional variants (either at the RNA orprotein level)
responsible for the phenotypes. Due to their abundance and
variability, SNPs have been considered powerful markers to
identify loci underlying phenotypic variation in genetic
association studies. To provide common and robust tools for
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has genotyped nearly 4 million SNPs from individuals of the
main human populations. A subset of these SNPs, covering the
genome at the physical and genetic levels, is included in the
commercially available arrays.
The outcome of the ﬁrst round of studies involving
thousands of patients and controls, and several hundred
thousand SNPs has recently been published. GWASs have
been completed for more than a dozen common disorders
(Table 1) and several new associations have been detected.
The Wellcome Trust Case Control Consortium (WTCCC) has
reported the largest genome-wide association study
performed so far, for seven diseases involving 14,000 patients
and 3,000 controls [2]. Together with the WTCCC study, other
publications (Table 1) have reported new, and conﬁrmed
previously known, statistically compelling associations for
common disorders, including type 1 [2,3] and type 2 diabetes
[2–7], obesity [2], coronary heart disease [2,8–10], breast [11–
13] and prostate [14,15] cancer, rheumatoid arthritis [2],
Crohn disease [2,16–18], celiac disease [19], asthma [20], age-
related macular degeneration [21], restless leg syndrome [22],
and multiple sclerosis [23].
The above-mentioned analyses represent an obvious step
forward in the arena of the study of the genetic contribution
to complex diseases and have undoubtedly proved the utility
of the GWAS approach using SNPs to identify new genetic
associations without previous hypotheses about their biology.
Each of these reports has described links with known or new
biological pathways, and has also established novel
mechanistic connections among pathways and among
disorders. The set of loci reported so far should potentiality
facilitate progress in the understanding of the physiology of
each of these disorders. These studies, however, raise several
questions in relation to the genetic basis of complex diseases
and the strategies used so far towards the identiﬁcation of a
complete set of susceptibility loci.
First, it is obvious that the genetic picture obtained for
each of these disorders, even for those targeted by
independent cohorts, such as in the case of type 2 diabetes, is
still far from complete. The identiﬁed associations, with some
exceptions (the major histocompatibility complex, MHC,
locus), have a modest effect with odds ratios lower than 1.5.
Thus, the nine conﬁrmed loci for type 2 diabetes [2–7] might
explain about 3% of the genetic variance, and 14 loci
identiﬁed for Crohn disease [2,16–18] cover less than 10% of
the variance. If we take into account the outcome achieved in
these studies using such large number of samples and SNPs, it
is expected that new associations for common disorders using
SNP markers will likely have similar or even lower effects, and
association values will likely not go far above current ﬁgures.
Furthermore, we are uncertain about how well the additional
small effects will be able to disclose the strong heritability
that many complex disorders exhibit.
Second, it is also obvious from the studies reported so far
(with the exception of age-related macular degeneration [21]
and some other disorders), that the identiﬁed variants are not
the functional ones. Thus, the role of most genetic changes in
the molecular basis of disorders has not yet been discovered.
Sequencing of a large number of patients with the
aforementioned disorders along with a deep coverage of the
Table 1. Associations Identified in GWASs for Common Disorders Using Genotyping Arrays
Disease Array Reference
Type 1 diabetes Affymetrix GeneChip 500K [2]
Custom (13K) [3]
Type 2 diabetes Affymetrix GeneChip 500K [2]
Illumina HumanHap300 BeadChip [6]
Illumina HumanHap500 BeadChip [4]
Illumina Human1 and HumanHap300 BeadChip [7]
Illumina HumanHap300 BeadChip [5]
Hypertension Affymetrix GeneChip 500K [2]
Coronary heart disease Custom (100K) [8]
Affymetrix GeneChip 500K [2]
Illumina HumanHap300 BeadChip [9]
Custom (100K) [10]
Breast cancer Illumina HumanHap500 BeadChip [12]
Illumina HumanHap300 BeadChip [13]
Perlegen Sciences (267K) [11]
Prostate cancer Illumina HumanHap300 BeadChip [14]
Illumina HumanHap500 BeadChip [15]
Bipolar disorder Affymetrix GeneChip 500K [2]
Rheumatoid arthritis Affymetrix GeneChip 500K [2]
Crohn disease Affymetrix GeneChip 500K [2]
Illumina HumanHap300 BeadChip [16]
Illumina HumanHap300 BeadChip [17]
Illumina HumanHap300 BeadChip [18]
Celiac disease Illumina HumanHap300 BeadChip [19]
Asthma Illumina HumanHap300 BeadChip [20]
Age-related macular degeneration Affymetrix GeneChip 100K [21]
Multiple sclerosis Affymetrix GeneChip 500K [23]
Restless leg syndrome Affymetrix GeneChip 500K [22]
doi:10.1371/journal.pgen.0030190.t001
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performed, and is already under way in some cases. This will
help to detect variants with functional consequences and
larger effects than those so far uncovered, even if they are
rare in the population and account only for a subset of
patients.
Third, it would be interesting to see if epistasis exists
between functional variants once they have been detected. It
is remarkable that the data obtained so far mainly show
absence of epistasis between variants for the same disorder or
groups of disorders. Speciﬁc screens should be performed to
assess the additive nature of the genetic component of the
identiﬁed associations.
Fourth, although the HapMap project has provided an
excellent tool for genetic association studies, it is clear that
the set of markers analyzed in GWASs do not cover the entire
genome variability. Despite the large number of SNPs that
have been selected to explore genetic association using LD
measures [24], and the coverage of nearly 100% of the
genome using between 0.5 and 1 million tagSNPs [25], some
regions are likely to be missed. Certainly, there are regions
not well covered in HapMap due to the lack of sequence
information, and, in large part, to the presence of CNVs and
segmental duplications [26,27]. This has caused commercial
panels to be deﬁcient in SNPs covering these regions. Thus,
future studies trying to reveal a more complete set of genetic
determinants will necessarily require a larger number of
SNPs (many with low minor allele frequencies and covering
‘‘unsettled’’ regions) and even larger cohorts. It has been
estimated that to identify the complete set of loci involved in
the genetic susceptibility to common disorders, sample sizes
in the range of 2,000 to 60,000, and denser genetic maps, over
1 million SNPs will be needed. Despite the claims for ‘‘denser
and larger,’’ the relatively large sample size of the studies
performed so far and the wide genome coverage achieved
suggests that, for some of the most deeply investigated
disorders, the common genetic variants that underpin their
genetic component have already been identiﬁed.
It seems clear that some of these questions will be solved by
simply analyzing larger sample sets with denser SNP arrays,
and by resequencing loci showing associations in a large
number of samples. However, it is obvious that we need to
explore the genome for other sources of variability that could
explain the strong genetic component of several of the
common disorders. Among sources to be explored are
noncoding RNAs, structural variants, and epigenetic changes.
Many Versions Account for the Human Genome
Sequence
When the human genome sequence was publicized six years
ago, it was openly claimed that genetic differences between
individuals account for less than 0.1% of the DNA sequence
[28,29], a total of about 3 million nucleotides. Certainly, the
statement referred to, and inferred from, the types of
markers that had been, until then, widely used to explore
diversity, construct genetic maps, and identify the genes
responsible for more than 2,000 human monogenic disorders
(http://www.ncbi.nlm.nih.gov/sites/entrez?db¼OMIM). These
markers included ‘‘old and new’’ types of polymorphisms,
comprising restriction fragment length polymorphisms [30],
variable number of tandem repeats or minisatellites [31],
short tandem repeats or microsatellites [32,33], insertion/
deletion polymorphisms [34], and the over 12 million SNPs
that have been deposited in the dbSNP database (http://www.
ncbi.nlm.nih.gov/SNP/).
In the last three years, a new form of genetic variation has
been extensively reported. Genome structural variation has
been known at the cytogenetic and molecular levels for a long
time [35–37], but its importance at a genome-wide scale was
not discovered until recently [38,39], with the use of array-
based comparative genomic hybridization and other types of
genome-scanning technologies. This variability entails large
segments of DNA, typically over one kilobase (kb) and up to
several megabases (Mb) and it comprises insertions, deletions,
translocations, and inversions of genomic material (Figure 1).
So far, the most commonly identiﬁed types of variants are
gains and loses of DNA, which are called CNVs [40].
Inversions are also likely to be important changes, with direct
potential positional effects and suppression of meiotic
recombination, but, with some exceptions [41,42], most
efforts toward characterization of variants have so far been
focused on other types of changes. Obviously, structural
variants are not exclusive of humans and they have also been
identiﬁed in other organisms [43,44].
Fifteen comprehensive studies have explored structural
variation in the human genome [38–41,45–52] (Table 2).
These studies have used several approaches, mainly bacterial
artiﬁcial chromosome (BAC) arrays, oligonucleotide arrays,
SNP arrays, genotyping data, and computational alignment of
genome sequences. There is wide variation of the coverage
provided by the different methods and the level of
polymorphism detected in the different studies (Figure 2).
Many reasons account for these differences, including type of
platform, genomic coverage, source of DNA samples (cell
lines or fresh samples), control samples used by the different
doi:10.1371/journal.pgen.0030190.g001
Figure 1. Types of Genomic Structural Changes Affecting Segments of
DNA, Leading to Deletions, Duplications, Inversions, and CNV Changes
(Biallelic, Multillelic, and Complex)
The only segment that is constant is ‘‘A.’’ Segment ‘‘B’’ varies in
orientation in the inversion. Segments ‘‘C’’ and ‘‘D’’ show different types
of variation.
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Comparison of experimental platforms, algorithms, and
published surveys has recently been reviewed [53]. It is clear
that the analysis of structural variants is still in its infancy, as
compared to SNPs, but we have to admit that CNV analyses
have additional complexity, due to their heterogeneity and
the poor coverage that they exhibit in the assembled
individual genomes [47].
The compilation of all reported variable regions is
provided at several Web sites, including the UCSC (http://
genome.ucsc.edu/) and Ensembl (http://www.ensembl.org/)
genome browsers, and the most updated summary can be
found at the Database of Genomic Variants (http://
projects.tcag.ca/variation/), which lists 8,083 CNVs that
correspond to 3,933 loci in the human genome assembly (7
September 2007).
After the initial discovery that CNVs are common in the
population, it was envisioned that CNVs might be traced
using SNPs as proxies for different alleles of the structural
changes. Although this is the case for some simple biallelic
CNVs [40], the most common and polymorphic ones have a
complex inheritance pattern and the SNPs located within do
not always show Mendelian inheritance or are not in Hardy–
Weinberg equilibrium. As a result of this, and also because of
their identity with related sequences due to segmental
duplications, many SNPs located at CNVs do not fulﬁll
quality-control criteria and have been discarded in the design
or in the analysis of genotyping experiments. Non-Mendelian
behavior has also posed difﬁculties in the use of SNPs for
tagging the inheritance of such variants. However, this
abnormal behavior of markers has been used to successfully
identify polymorphic deletions and inversions [42,50–52].
Since CNVs are not tagged easily by SNPs, many fall in
regions that are not well deﬁned in the available human
genome sequence, and SNP content in commercial platforms
is skewed towards ‘‘genotypable’’ SNPs present in the
HapMap, it is likely that most GWASs (Table 3) have missed
the potential contribution of CNVs to complex disorders. As
mentioned above, our understanding of the organization of
CNVs and their heritability is still very rudimentary. CNVs
are likely to affect recombination, and the relationship with
other markers might be relevant for common CNVs.
The current knowledge of CNVs is far from complete,
because technological limitations of the approaches used so
far to ascertain them have introduced an important bias
towards medium-to-large-size CNVs. While technology has
done very well for CNVs of sizes above 50 kb, smaller CNVs
have hardly been detected. As further studies are performed
covering regions below the 50-kb range, it is expected that a
large number of additional CNVs, likely on the order of tens
of thousands, will be detected (Figure 3). Considering the
current human genome assembly, structural variants cover
about 15% of the sequence (over 500 Mb). This ﬁgure is,
however, imprecise, due to the lack of consensus in
boundaries of CNV regions, the low level of resolution of
clone arrays, and the near absence of replication of the
reported data. On the basis of the expected size distribution
of CNVs, they could likely affect up to one gigabase of
sequence (;1/3 of the genome). What is clear so far is that
there is not a single human genome sequence and that several
conﬁgurations, with alternative sequences at CNV regions,
are present in the human population. Technologies that are
able to screen the genome below this resolution will be
essential. This should involve arrays speciﬁcally designed to
interrogate at the 1–50-kb scale and sequencing speciﬁc
regions with methods that allow the selection of DNA without
previous knowledge of the sequence. In addition, efforts
towards sequencing the genomes of different individuals to
uncover their variability at the structural level are under way
[54].
Rare and Common CNVs Are Involved in Complex
Disorders
CNVs have already been shown to be associated with
several complex/common disorders. Interestingly, most of
these ﬁndings have been obtained by speciﬁc analysis of
candidate genes or regions. Rare CNVs have been detected in
some families of patients affected by Parkinson disease,
Alzheimer disease, and chronic pancreatitis. Multiple cases of
Table 2. Summary of Genome Scans to Study Structural Variations and CNVs of the Human Genome
Study Method—Coverage Detects Samples Variants
[38] BAC array—5,000 clones Deletion/insertion 55 255
[45] BAC array—2,000 clones Deletion/insertion 47 160
[46] BAC array—2,000 clones Deletion/insertion 269 222
[40] BAC array—26,000 clones Deletion/insertion 270 1,116
a
[48] BAC array—26,000 clones Deletion/insertion 95 3,654
[40] Affymetrix 500K GeneChip Deletion/insertion 270 1,203
a
[49] Illumina Human1 and HumanHap300 BeadChip Deletion/insertion 182 340
[39] ROMA—85,000 oligonucleotides Deletion/insertion 20 76
[50] Genotyping data—100–200 Mb Deletion 24 215
[52] Genotyping data—1.3 million genotypes Deletion 180 586
[51] Genotyping data—1.3 million genotypes Deletion 269 541
[42] Genotyping data—1.3 million genotypes Inversions 269 176
[41] Fosmid end sequencing/mapping Deletion/insertion/inversion 1 297
[34] Computational alignment between genomes Deletion/insertion/inversion 36 294,498
[47] Computational alignment between genomes Deletion/insertion/inversion 2 13,534
aCorrespond to copy number variant regions (CNVRs), each involving several CNVs. Detailed information on CNVs and references can be found at http://projects.tcag.ca/variation/.
doi:10.1371/journal.pgen.0030190.t002
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or triplication of the alpha-synuclein gene (SNCA) have been
reported to cause hereditary early-onset parkinsonism with
dementia, demonstrating a direct relationship between SNCA
gene dosage and disease progression [55–57]. Similarly,
several cases of duplication of the amyloid precursor protein
(APP), with a role in familial Alzheimer disease and in Down
syndrome brain neurodegeneration, have been described in
families with early-onset Alzheimer dementia with cerebral
amyloid angiopathy [58–60]. Finally, some members of
families affected by hereditary pancreatitis have duplications
or triplications of the cationic trypsinogen gene (PRSS) [61].
It is clear that in these three common disorders, the CNVs
associated with the respective diseases represent rare events,
and are not the major mechanism for disease susceptibility.
Thus, rare genomic rearrangement events could affect
common disorders in a manner similar to what has been
reported for monogenic diseases, such as Neuroﬁbromatosis
type 1, for which large deletions are detected in about 10% of
patients [62]. However, since rare CNVs are abundant in the
genome, they could represent an important source of
variability with which to explore the relationship between
candidate genes and disease, and therefore to deﬁne new
pathophysiology pathways.
Common CNVs have also been detected in people affected
by certain other disorders. For example, variability in the
susceptibility to HIV-1 infection has been related to copy
number of the CCL3L1 gene [63]. Individuals with low copy
numbers of the chemokine gene, relative to their ethnic
background, are associated with markedly enhanced HIV-1/
AIDS susceptibility. More recently, differences in copy
number of the CCL3L1 chemokine have also been reported as
a susceptibility factor for rheumatoid arthritis [64]. This
region was not targeted in HapMap phases I and II and is not
well covered by the Affymetrix and Illumina arrays;
consequently, any attempt to perform association studies for
HIV-1 susceptibility will likely fail in detecting a putative link
with CCL3L1 copy variability (Figure 4). This region shows a
large variability, not only in CCL3L1 copy number, but also in
the genomic structure of individuals from different
populations, as detected in the HapMap samples that have
been genotyped [40]. In particular, the region is highly
doi:10.1371/journal.pgen.0030190.g002
Figure 2. Approaches Used for the Identification of CNVs and Other Types of Structural Changes in the Human Genome
Myriad methods and technologies have been employed to identify structural variants in the human genome. They are based on completely different
experimental procedures and provide very different levels of resolution. The majority of findings (.80%) are attributable to a restricted number of high-
throughput experiments with a limited resolution.
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copy number gains in Africans and Asians, compared to
Europeans.
Similarly, a copy number polymorphism including FCGR3
leads to a predisposition to glomerulonephritis in rats and
humans, and to several types of autoimmune disorders, such
as systemic lupus erythematosus (SLE), microscopic
polyangiitis, and Wegener granulomatosis [65,66]. This region
contains a complex 82-kb segmental duplication in the
assembled genome sequence and CNVs have been detected in
several studies in samples from the general population
[40,46,48]. The coverage of the region is only partial in
commercial arrays and the region of the CNVs and segmental
duplication has a very low LD, with no blocks detected in
HapMap populations.
Recently, another CNV region has been shown to be
associated with SLE. Variable copy number of the
complement component C4 (C4A and C4B) leads to different
Table 3. Summary of Common Disorders for Which Associations to CNVs Have Been Reported
Disorder CNV SD SNPs
a Gene Effect Risk Associated Study Type Significance Reference
HIV-1/AIDS susceptibility Common Yes No CCL3L1 Dosage Low CNV Case control Varies in
populations
[63]
Rheumatoid arthritis and
Type 1 diabetes
Common Yes No CCL3L1 Dosage High CNV Case control OR ¼ 1.34;
p ¼ 0.009
[64]
SLE, microscopic Polyangiitis,
and Wegener granulomatosis
Common Yes No FCGR3B Dosage Low CNV Case control p ,0.001 [65,66]
SLE Common Yes No C4A/C4B Dosage Low CNV Case control OR ¼ 6.5;
p , 0.00002
[67]
Crohn disease Common Yes No DEFB4 Dosage Low CNV Case control OR ¼ 3.6
p , 0.008
[71]
Bipolar disorder Common No Poor GSK3B Positional High copy number Case control p ¼ 0.002 [72]
Early-onset Parkinson disease Rare No Yes SNCA Dosage Duplication/triplication Familial NA [55,56,57]
Hereditary early-onset
Alzheimer disease
Rare No Yes APP Dosage Duplication Familial NA [59,60]
Hereditary pancreatitis Rare Yes Poor PRSS1 Dosage Triplication Familial NA [61]
Autism spectrum disorders Common NA Vary Multiple Unknown Higher ‘‘de novo’’ CNVs;
multiple CNVs
Familial NA [78,79]
Familial breast cancer Common No Yes MTUS1
(exon 4)
Positional Exon deletion
confers lower risk
Familial OR ¼ 0.41;
p , 0.003
[73]
aSNP coverage in the Affymetrix and Illumina panels used in GWASs and HapMap genotyped SNPs. No, absence of SNPs; Yes, presence of SNPs; Poor, partial coverage; Vary, several regions
with different types of coverage.
SD, segmental duplication; NA, not applicable; OR, odds ratio; p, p-value;
doi:10.1371/journal.pgen.0030190.t003
doi:10.1371/journal.pgen.0030190.g003
Figure 3. Expected and Observed Size Distribution of CNV Changes Identified to Date
Blue bars represent the frequencies of the currently identified CNVs in the size ranges depicted in the x-axis. A plausible scenario of variation in CNV size
frequency is depicted as red vertical bars. An under-detection of variable fragments of small size (,50 kb) can be observed, which is likely due to
technological limitations in the high-throughput assays used so far to identify CNVs, largely based on array CGH (Figure 2). Observed and expected
CNVs that are .50 kb coincide, due to the powerful array methods, which cover the medium-to-large-size CNVs well. Dark blue bars represent the
small-sized CNVs, which are more of a challenge to detect.
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from two to six for total C4, zero to ﬁve for C4A, and zero to
four for C4B. Compared with healthy subjects, patients with
SLE clearly have lower copy numbers of C4 and C4A, and SLE
susceptibility is signiﬁcantly increased among subjects with
only two copies of total C4 but decreased in those with more
than ﬁve copies of C4 [68]. Interestingly, variability in copy
number for the C4 genes and the genetic association to
markers in this MHC region on Chromosome 6p21.32 has
been known for several years [67,69,70], but their complex
organization and their relationship with SLE has not yet been
examined in detail. The C4A gene is fully contained in a 33-kb
segmental duplication that shows 99.6% identity between
copies in the assembled sequence of the human genome. The
region has also been reported to be polymorphic in two
studies exploring CNV regions [40,41]. This 80-kb region is
not covered by the Affymetrix and Illumina arrays, and only
three SNPs have been genotyped in HapMap, precluding
positive association ﬁndings to these genes in whole-genome
association studies (Figure 5).
Another report has detected variability in copy number of
the beta defensin 2 gene (DEFB4) on Chromosome 8p23.1 in
Crohn disease [71]. DEFB4 dosage is lower in colonic Crohn
disease compared with controls, showing that a lower DEFB4
gene copy number predisposes to colonic Crohn disease
through diminished beta-defensin expression. Again, for this
locus, there is a cluster of segmental duplications, and most
CNV studies have detected this region as being variable. This
region, which spans about 1 Mb and contains a gap in the
assembled genome sequence, has only four SNPs in the
Affymetrix array and one in the Illumina array (not shown).
Although the region was not detected in the GWAS for Crohn
disease [2,16–18], it is obvious that this region was not
satisfactorily covered by these arrays. Only the targeted
analysis of the region using quantitative methods was able to
uncover the link with Crohn disease [71].
Finally, several other studies exploring CNVs in common
doi:10.1371/journal.pgen.0030190.g004
Figure 4. Genomic Organization of the Chemokine Cluster on Human Chromosome 17, Containing the CCL3L1 Gene (Red Arrows), Which Shows
Variability in Copy Number and Association to HIV-1 Infectivity and AIDS Susceptibility
This region contains several segmental duplications and has been reported to vary in copy number in several studies. The Affymetrix 500K and Illumina
HumanHap 550 arrays do not cover this region well, and completely lack SNPs in the CCL3L1/L3 gene (red dotted lines). A large number of gains and
losses have been reported in the HapMap samples. Numbers in parentheses indicate the number of events involving genomic changes.
CEU, European; HCB, Chinese; JPT, Japanese; YRI, African.
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disorder [72] and breast cancer [73] have already been
reported. Therefore, we expect that there will be a plethora
of reports describing new associations between CNVs and
common disorders and complex traits in the coming months
to years.
A common feature of the regions for complex/common
disorders identiﬁed so far is the presence of both CNVs and
segmental duplications. A clear association between
duplicons and CNVs in the human genome has been reported
[40]. This association is stronger for CNVs that are
multiallelic or have a complex pattern. Interestingly, all CNV
loci that have been found associated with common disorders
are both complex and multiallelic. Thus, the development of
assays for common/complex CNV loci could provide good
tools for the analysis of common disorders.
The mechanisms by which CNVs could contribute to
disease are numerous [74]. Due to their location and nature, a
signiﬁcant fraction of CNVs are likely to have functional
consequences, either by gene dosage alteration, disruption of
genes, positional effects, uncovering deleterious alleles, or
modulating the action of other sequences. We still have
limited evidence of the role of CNVs in gene expression.
Stranger and colleagues [75] have examined RNA levels in
lymphoblastoid cell lines from 210 unrelated HapMap
individuals and have used CNV data from these samples
generated by the Structural Variation Consortium [40] to
conclude that 18% of the variation in expression levels of
;15,000 genes is attributable to copy number differences.
This study represents the ﬁrst attempt to evaluate the
genome-wide impact of SNPs and CNVs on gene expression.
A potential explanation for the relatively low contribution of
CNVs to variability of gene expression as compared to SNPs
in the study of Stranger and colleagues [75] is the limited
resolution of the arrays used and the wide deﬁnition of CNV
regions considered in the analysis.
Combination of SNP and CNV Genotyping in
Common Disorders
Although a large number of SNPs for regions containing
CNVs are listed in dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP/), most of them lack genotyping frequencies,
have not been conﬁrmed by other investigators, or fail during
the design of multiplex genotyping assays. Many of these
SNPs are located in segmental duplications and they
correspond to paralogous sequence variants or SNPs that are
copy speciﬁc [76]. As a consequence, most of these regions
have systematically been excluded from the current high-
throughput SNP typing assays.
Many investigators in the ﬁeld of the genetics of common
disorders have realized the need to cover other types of
variants in their genome scans. Commercial genotyping
companies (mainly Affymetrix and Illumina) are redesigning
their platforms to allocate probes for CNV regions and they
now claim a genome-wide coverage of known and new CNVs.
While this reﬂects the recent attention that CNVs have
attracted in the genotyping ﬁeld, the reliability of the
coverage and the capacity of these arrays to discriminate
between a wide range of copies of a given CNV has yet to be
proven. This discrimination capacity is one of the main
challenges to extracting the complexity of genomic structural
variability and will be crucial for association studies. On the
other hand, companies dedicated to array–comparative
genomic hybridization (CGH) production (Nimblegen and
Agilent) are developing denser arrays that could explore the
complete genome, also offering ﬂexibility in the
incorporation of probes for targeted studies. A review about
the different platforms available for CNV analysis has
recently been published [77]. There are many reasons for and
against the use of one over another. While genotyping
platforms provide two products for the price of one, CGH
arrays provide better signal accuracy, because they compare
real samples in the same experiment. The choice depends on
the speciﬁc status of the project, especially if a GWAS has
already been performed with ﬁrst-generation genotyping
arrays, which have poor coverage in CNV regions. In these
cases, CGH arrays should provide coverage of CNVs missed
by the genotyping platforms. Indeed, several efforts are under
way to screen, using CGH platforms, the WTCCC samples
already genotyped with Affymetrix arrays (Figure 6).
It is important to note that all the associations between
CNVs and complex disorders reported so far have been
unveiled through candidate gene or candidate region
approaches. Indeed, only thorough investigations by groups
working on the disorders or with speciﬁc interest in a
concrete variable region have been able to dissect the ﬁne
spectrum of variability to provide a link with the phenotypes
(Table 3). Although genotyping scans could be able to detect
CNV regions, current approaches do not provide any kind of
discrimination of the variability spectrum associated to these
loci, and are therefore unable to distinguish copy numbers
with respect to phenotype. Several methods allow
quantiﬁcation of CNVs, including multiplex ligation-
dependent probe ampliﬁcation (MLPA), multiplex
ampliﬁcation and probe hybridization (MAPH), quantitative
multiplex PCR of short ﬂuorescent fragment (QMPSF),
dynamic allele-speciﬁc hybridization, semiquantitative
ﬂuorescence in situ hybridization (SQ-FISH), paralogue ratio
test, and multiple amplicon quantiﬁcation, among others
(Figure 6). Precise deﬁnition of breakpoints can be achieved
by PFGE (pulsed ﬁeld gel electrophoresis), regular Southern
blotting, and sequencing. Ultrasequencing technologies
(based on synthesis, GS-FLEX [Roche-454] and 1G Solexa
Genetic Analyzer [Solexa-Illumina]; or on ligation, SOLiD
[Applied Biosystems]) should also provide this level of
resolution, but speciﬁc experimental trials have to be
developed to achieve a successful resequencing and assembly
Figure 5. Schematic Representation of Two Genomic Regions That Involve CNVs Associated with SLE [65,66]
(A) The region of Chromosome 1 containing the FCGR3 gene cluster is highly variable and contains segmental duplications with a high sequence
identity. Several CNVs have been reported that span this region. The genomic organization of the cluster is highly complex and not well solved in the
current assembly of the genome sequence. The Affymetrix 500K and Illumina HumanHap 550 arrays do not cover this region well (red dotted lines).
(B) The region of Chromosome 6p21, containing the C4A and C4B genes, is embedded in a region of complex genomic organization [67,69,70]. The
region has been shown to contain segmental duplications and CNVs. The Affymetrix 500K and Illumina HumanHap 550 genotyping platforms do not
cover this region, either (red dotted lines).
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CNVs. Tailored approaches to detect the variability in copy
number of common CNV loci, and the use of genetic
approaches that explore the differences between phenotypes
at a whole-genome scale should be pursued. A diagram of
genome-wide and locus-speciﬁc approaches to detect and
analyze CNVs is proposed in Figure 6. Improvements in the
ﬁeld of CNVs are clearly needed both for the genome-wide
coverage and for the precise quantiﬁcation of speciﬁc CNVs.
Progress in the identiﬁcation of CNVs associated with
complex disorders will likely take place at a rapid pace in the
next few months to years. Currently available tools will only
be able to disclose variants that, because of their genomic
(large rearrangements) and genetic characteristics (de novo
cases), are easily discovered [78,79]. Thus, the systematic
exploration of multiallelic CNVs, with precise
characterization of copy numbers, should become essential
when exploring the role of CNV in many traits and diseases.
Finally, since many CNVs contain genes with an important
role in adaptation to the environment and response to
external effects [40], it is tempting to speculate that CNV
alleles could have a major role in disease predisposition and
response to drugs.
Conclusions
Recent progress in the identiﬁcation of loci showing
association to complex disorders has provided not only a
proof of concept of GWASs, but has also led to the
identiﬁcation of several new biological associations. The need
for larger sample sets and better coverage of genome
variability at the nucleotide level, including resequencing, is
likely to be achieved after this initial ﬁrst round of GWASs.
However, the complete spectrum of genomic variability will
not be elucidated by this approach. Several CNVs have been
shown to be implicated in common disorders, as rare and
common genomic changes, providing biological support to
several pathophysiological pathways. New types of arrays,
covering CNVs and segmental duplications, will facilitate the
identiﬁcation of regions that contain CNVs, but will likely
still fail to detect associations with a wide range of variability
in copy number. A comprehensive tailored analysis of
common and rare CNVs will not only complement GWASs
using SNPs and sequencing, but will also provide a new, more
powerful tool for examining the genetic components of
common disorders and complex traits in humans and other
organisms. “
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